Last edition
News about "clinical development "
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Clinical Development | 25/03/2026 | By News Bureau | 181
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
Clinical Development | 21/03/2026 | By News Bureau | 247
Andera Partners Targets EUR 10 Billion AUM as It Accelerates Innovation and European Expansion
Andera Partners is reinforcing its long-term growth strategy by combining sustained investment activity, active portfolio management and strong fundraising momentum, despite a challenging economic environment marked in 2025 by a global slowdown and a more than 20 percent decline in private equity investments in France.
<br />
Clinical Development | 23/02/2026 | By Darshana | 324
Newron Strengthens Clinical Development Funding with Multi-Tranche Share Deal
Newron Pharmaceuticals has secured a staged equity financing agreement worth up to EUR 38 million from a consortium of existing and new investors in Europe and Asia, strengthening its balance sheet as it advances late-stage clinical development of evenamide for treatment-resistant schizophrenia.
Clinical Development | 18/02/2026 | By Darshana | 144
Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies
Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.
Clinical Development | 11/02/2026 | By News Bureau | 141
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Clinical Development | 21/01/2026 | By News Bureau | 217
Genethon Partners with AskBio on Pompe Gene Therapy
The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.
Clinical Development | 15/01/2026 | By News Bureau | 123
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Clinical Development | 01/12/2025 | By Dineshwori | 165
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Clinical Development | 01/12/2025 | By Dineshwori | 165
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Clinical Development | 12/11/2025 | By Dineshwori | 691
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy